emerge weight loss semaglutide (Wegovy) might help with more than just loss.⁣ ⁣ In a new 26-week randomized controlled trial (PMID: 42070571), participants with obesity and alcohol use disorder taking semaglutide 2.4 mg/week had Online Tirzepatide & GLP-1 Weight

Full-year 2024 revenues are expected between $1.20 billion and $1.23 billion versus $1.19 billion consensus estimates

Under the agreement, the two parties will collaborate on the clinical development, regulatory filing, and commercialization in South Korea of Bofanglutide Injection, a bi-weekly (once every two weeks) Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) independently discovered and developed by Gan & Lee

Because these are powerful medications, they are strictly FDA-approved for chronic weight management in specific populations

doi:10.1056/NEJMoa1916038 51 KissowHHartmannBHolstJJVibyN-EHansenLSRosenkildeMMet al